Evidence map›Paper›PMID 30887156›Full record

ArticleJournal of cancer research and clinical oncology2019

Impact of nodal status and treatment strategy on overall survival in advanced stage cervical cancer.

Thomas Papathemelis, Stella Knobloch, Michael Gerken, Anton Scharl, Michael Anapolski, Atanas Ignatov, Elisabeth C Inwald, Olaf Ortmann, Sophia Scharl, Monika Klinkhammer-Schalke

Open access · greenAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Thomas PapathemelisDepartment of Gynecology and Obstetrics, Klinikum St. Marien Amberg, Amberg, Germany. papathemelis@web.de.ORCID http://orcid.org/0000-0003-1805-2610
Stella KnoblochTumor Center, University of Regensburg, Regensburg, Germany.
Michael GerkenTumor Center, University of Regensburg, Regensburg, Germany.
Anton ScharlDepartment of Gynecology and Obstetrics, Klinikum St. Marien Amberg, Amberg, Germany.
Michael AnapolskiDepartment Ob/Gyn, University of Witten-Herdecke, KKH Dormagen, Dormagen, Germany.
Atanas IgnatovDepartment of Gynecology and Obstetrics, University Medical Center, Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany.
Elisabeth C InwaldDepartment of Gynecology and Obstetrics, University Medical Center, Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany.
Olaf OrtmannDepartment of Gynecology and Obstetrics, University Medical Center, Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany.
Sophia ScharlDepartment of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München (TUM), Ismaninger Straße 22, 81675, Munich, Germany.
Monika Klinkhammer-SchalkeTumor Center, University of Regensburg, Regensburg, Germany.
University Hospital Regensburg · DEUniversity of Regensburg · DEKlinikum St. Marien Amberg · DEKreiskrankenhaus Dormagen · DETUM Klinikum · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe lack of prognostic data impedes implementation of optimal therapy for cervical cancer. For instance, recommended therapy for FIGO IIB cervical cancer is radical hysterectomy or radiochemotherapy. To enlighten different therapeutic approaches, we investigated the benefit of individual therapies or combination thereof in patients with or without infested lymph nodes.

methodsThe German Tumor Centre Regensburg registered 389 patients with FIGO IIB, IIIA, IIIB, and IVA cervical cancer between 2002 and 2015. We estimated hazard ratios (HR) for overall survival against different therapies using univariable and multivariable cox regression. After risk adjustment with respect to clinicopathological parameters, we performed model selection using conditional stepwise reverse selection.

resultsWe demonstrated the need for thorough assessment of the nodal status to obtain reliable data for treatment strategy. Our analysis showed significant differences for overall survival in FIGO IIB depending on therapy and nodal status. Outcome was inferior with radiochemotherapy without surgery for patients with N0 compared to surgery and radiochemotherapy combined (HR 3.012; 95% CI 1.075-8.441; p = 0.036); however, for N1, radiochemotherapy without surgery resulted in comparable outcome (HR 0.808; 95% CI 0.189-3.403; p = 0.765), whereas surgery alone yielded in poor outcome (HR 2.889; 95% CI 1.356-6.156; p = 0.006). Regardless of the nodal status, chemotherapy was superior in advanced stage cervical cancer FIGO III to IVA.

conclusionsOur study suggests that in terms of oncological outcome FIGO IIB cervical cancer patients benefit from a combination of surgery and radiochemotherapy. However, in the presence of lymph node infestation, surgery does not add substantial benefit to the patient.

Indexed as

AdultAgedAged, 80 and overCombined Modality TherapyComorbidityFemaleHumansKaplan-Meier EstimateLymphatic MetastasisLymph Node ExcisionLymph NodesMiddle AgedNeoplasm StagingRetrospective StudiesUterine Cervical NeoplasmsYoung AdultCervical cancerLymphadenectomyNodal statusOutcomeOverall survivalTherapy

Identifiers

PMID30887156
PMCPMC11810329
OpenAlexW2921665354

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.